Werewolf Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Werewolf Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q3 2024.
  • Werewolf Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $2.01M, a 4.1% decline year-over-year.
  • Werewolf Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $8.79M, a 8.84% increase year-over-year.
  • Werewolf Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8.01M, a 8.22% increase from 2022.
  • Werewolf Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7.4M, a 80.7% increase from 2021.
  • Werewolf Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $4.1M, a 548% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $8.79M $2.01M -$86K -4.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $8.88M $2.6M +$672K +34.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $8.21M $2.31M +$197K +9.35% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-03
Q4 2023 $8.01M $1.87M -$69K -3.55% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 $8.08M $2.1M +$161K +8.32% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $7.92M $1.93M +$153K +8.61% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $7.76M $2.11M +$363K +20.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-03
Q4 2022 $7.4M $1.94M +$646K +49.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 $6.75M $1.94M +$457K +30.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $6.3M $1.78M +$996K +128% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $5.3M $1.75M +$1.21M +224% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $4.1M $1.3M +$1.08M +486% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 $3.02M $1.48M +$1.35M +1012% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $1.67M $781K +$560K +253% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $1.11M $539K +$482K +846% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $632K $221K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $133K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $221K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $57K Jan 1, 2020 Mar 31, 2020 10-Q 2021-06-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.